PwC welcomes a record 104 Saudis in annual graduate intake

Riyadh Al-Najjar, PwC KSA Country Senior Leader
Updated 29 September 2019

PwC welcomes a record 104 Saudis in annual graduate intake

PricewaterhouseCoopers (PwC) in Saudi Arabia welcomed 104 new graduates to its offices in the Kingdom. The new graduates are part of a larger pool of 322 new graduates who joined PwC across its 12 offices in the Middle East.
With the Kingdom ushering in a new era of change and a strong focus on nurturing and developing its local talent, this year’s PwC graduate intake, a record of 100 percent Saudi nationals, is a testament to the efforts already underway. PwC aims to play its part in bringing the Kingdom’s Vision 2030 to life and contribute to the local economy.
Riyadh Al-Najjar, PwC KSA country senior leader, said: “With the ever-changing trends shaping our region — from technological breakthroughs all the way through to demographic, socioeconomic shifts, resource scarcity among others — helping the communities in which we live and work to navigate these waves and help solve their most important problems has always been part of our DNA as a firm.

INNUMBERS

100% of KSA graduates are Saudi nationals.

35% of KSA graduates are women.

“We are also extremely proud of the fact that almost 35 percent of our new grads are women — our desire to help build the future female leaders of tomorrow continues to be a key priority for
our firm.”
PwC Middle East People Partner Emma Campbell said: “At PwC, we are proud to provide the opportunity for graduates to be themselves, to work on their individual growth and to unlock their potential by offering them a fulfilling career and a rewarding professional journey within the firm. Technology, automation and artificial intelligence are disrupting how we work in this rapidly changing world; yet human intervention is always needed to help us achieve our purpose.
“We are committed to developing young talent and to pave the way for the leaders of tomorrow as part of our continued confidence to invest in the region.”
The graduates attended an induction session in Dubai, in which they interacted closely with the Middle East leadership team and received an overview of the firm and its strategy.


Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

Updated 27 May 2020

Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

  • Trials are being led locally as an essential means to verify the safety and effectiveness of a new drug
  • Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic

RIYADH: Clinical trials in Saudi Arabia could speed up the adoption of new drugs locally, a pharmaceutical executive has told Arab News.

“Clinical trials have two very big benefits for the Kingdom. Firstly, they provide data in the long run with respect to safety and efficacy, catered specifically to the Saudi population. Secondly, they impact local investment and build healthcare capabilities,” Managing Director of Eli Lilly Dimitri Livadas said..

Lividas further explained that the clinical trial phase of any new treatment is crucial as it represents the stage between the adoption or rejection of a drug. Working with the Ministry of Health and with a presence in the Kingdom for 42 years, the pharmaceutical company began research trials in the country in 2016, consisting of five pre-marketing activities and three monitoring studies for post-marketing.

Lividas added that the trials are being led locally as an essential means to verify the safety and effectiveness of a new drug before it is put to the market and introduced to patients. The majority of these are focused on diabetes, oncology, immunology, and osteoporosis.

“We genuinely believe that our future is here in Saudi Arabia. We continue to make great progress in having a commercial organization in the Kingdom that is fully staffed by Saudi nationals,” said Lividas.

As a biopharmaceutical company, Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic. It recently announced partnership with AbCellera to develop a treatment for the virus and aims to enter into clinical trials this year.

“I salute the Saudi authorities for their strong measures to contain the spread of COVID-19. I think it is an example to the world on how to do this. I would like to also express my gratitude toward all healthcare professionals who are currently on the frontlines, risking their own health to help others," Lividas said.